Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors

Patent metadata

Field	Value
Publication number	US-12528827-B2
Application number	US-202318530405-A
Country	US
Kind code	B2
Filing date	Dec 6, 2023
Priority date	Jul 14, 2016
Publication date	Jan 20, 2026
Grant date	Jan 20, 2026

Abstract

Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R3 is a tricyclic heteroaryl group substituted with R3a and zero to 2 R3b; and R1, R2, R3a, R3b, R4, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

First claim

What is claimed is:

1 . A compound of Formula (II):

or a salt thereof; wherein:
R 1 is F, Cl, —OH, C 1-4 alkyl, C 1-4 fluoroalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 3-7 fluorocycloalkyl, C 1-4 alkoxy, C 1-4 fluoroalkoxy, C 2-4 hydroxyalkoxy, C 3-6 cycloalkoxy, (C 1-3 alkoxy)-(C 1-3 alkylene), (C 1-3 alkoxy)-(C 1-3 fluoroalkylene), (C 1-3 deuteroalkoxy)-(C 1-3 deuteroalkylene), (C 1-3 fluoroalkoxy)-(C 1-3 alkylene), (C 1-3 fluoroalkoxy)-(C 1-3 fluoroalkylene), —(CH 2 ) 1-3 O(phenyl), —(CH 2 ) 1-3 NR a R a , —C(O)O(C 1-6 alkyl), —C(O)NR a R a , —C(O)NR b R b , —NH 2 , —NH(C 1-6 alkyl), —N(C 1-6 alkyl) 2 , azetidinyl, pyrrolidinyl, furanyl, pyranyl, piperidinyl, morpholinyl, piperazinyl, —S(O) 2 (C 1-3 alkyl), —S(O) 2 NR a R a , C 1-3 alkylthio, or C 1-3 fluoroalkylthio;
R 2 , at each occurrence, is independently H, F, Cl, Br, —OH, —CN, C 1-4 alkyl, C 1-4 fluoroalkyl, C 1-4 hydroxyalkyl, C 1-3 aminoalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 3-7 fluorocycloalkyl, C 1-6 alkoxy, C 1-3 fluoroalkoxy, C 1-3 alkylthio, C 1-3 fluoroalkylthio, (C 1-3 alkoxy)-(C 1-3 alkylene), (C 1-3 fluoroalkoxy)-(C 1-3 alkylene), —C(O)NH 2 , —C(O)NH(C 1-6 alkyl), —C(O)N(C 1-6 alkyl) 2 , —C(O)NR b R b , —CH(OH)(C 3-6 cycloalkyl), —CH(OH)(phenyl), CH(OH)(pyridyl), —S(O) 2 (C 1-3 alkyl), —S(O) 2 NR a R a , or a cyclic group selected from phenyl, 5- to 6-membered heteroaryl, and 5- to 7-membered heterocycle, wherein said cyclic group is substituted with zero to 5 substituents independently selected from F, Cl, hydroxy, C 1-3 alkyl, C 1-3 alkoxy, cyclopropyl, and —CN;

R 3 is:

(i) X 1 is N and X 2 is S, O, or NH;
(ii) X 1 is O and X 2 is CH or N;
(iii) X 1 is NH and X 2 is CH; or
(iv) X 1 is CH and X 2 is S or NH;
and the dashed lines represent the variable position of a double bond to maintain aromaticity, each R 3 is substituted with R 3a and zero to 3 R 3b ;
R 3a is:
(i) H, C 1-6 hydroxyalkyl, C 1-6 hydroxyfluoroalkyl, —C(O)O(C 1-6 alkyl), —CR a R a NHC(O)(C 1-6 alkyl), —CR a R a NHC(O)(C 1-6 fluoroalkyl), —CR a R a NHC(O)O(C 1-6 alkyl), —CR a R a NHC(O)O(CH 2 ) 1-3 (C 1-3 alkoxy), —CR a R a NHC(O)O(C 1-4 fluoroalkyl), —CR a R a NHS(O) 2 (C 1-3 alkyl), CR a R a NHS(O) 2 (C 1-3 fluoroalkyl), —CR a R a OP(O)(OH) 2 , —CR a R a NHC(O)R x , —CR a R a NHC(O)OR x , —CR a R a NHC(O)CH 2 R x , —CR a R a NHC(O)OCH 2 R x , —CR a R a OC(O)NHR x , —CR a R a NHC(O)NHR x , —CR a R a OR x , or —CR a R a OC(O)R x ;
(ii) —CH(OH)CR h R i R j wherein R h and R 1 are independently H, F, C 1-4 alkyl, C 1-4 fluoroalkyl, C 1-3 alkoxy, or C 1-3 fluoroalkoxy, or taken together with the carbon atom to which they are attached, form C 3-8 cycloalkyl or 4- to 7-membered heterocyclyl ring; and R j is H, C 1-6 alkyl, C 1-s fluoroalkyl, (C 1-3 alkoxy)-(C 1-3 alkyl), C 3-8 cycloalkyl, C 3-8 heterocyclyl, aryl, or heteroaryl;
R x is C 3-6 cycloalkyl, phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzo[d]oxazolyl, benzo[d]thiazolyl, pyrrolopyridinyl, tetrahydroisoquinolinyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, imidazopyridinyl, or oxo-dihydrobenzo[d]oxazolyl, each substituted with zero to two substituents independently selected from F, Cl, Br, —CN, —OH, —CH 3 , —CF 3 , C 1-3 alkoxy, C 1-3 fluoroalkyl, C 1-6 hydroxyalkyl, C 1-6 hydroxyalkoxy, C 1-6 hydroxy-fluoroalkoxy, phenoxy, —NR a R a , —C(O)NR a R a , —C(O)NH(C 1-6 alkyl), —C(O)N(C 1-6 alkyl) 2 , —C(O)NR b R b , —C(O)NR a (C 1-6 hydroxyalkyl), —C(O)O(C 1-6 alkyl), —C(O)OC 1-4 alkyl, —C(O)(morpholinyl), —S(O) 2 NR a R a , —CH(OH)CH 2 OH, —CH═CH 2 , —NHC(O)CH 3 , —OCH 2 CH 2 N(CH 3 ) 2 , —OCH 2 CH 2 OH, —OCH 2 CH(Me)OH, isoxazolyl, phenyl, pyrrolidinyl, thiophenyl, and methyl triazolyl;
R 3b , at each occurrence, is independently H, F, Cl, Br, —CN, C 1-3 alkyl, C 1-3 fluoroalkyl, C 1-3 hydroxyalkyl, —OCHF 2 , C 3-6 cycloalkyl, C 3-6 fluorocycloalkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 1-3 alkoxy, C 1-3 alkylthio, or C 1-3 fluoroalkoxy;
R 4 is H, F, Cl, or —CH 3 ;
R a , at each occurrence, is independently H, C 1-4 alkyl, or C 1-4 fluoroalkyl;
two R b along with the nitrogen atom to which they are attached form a 4- to 7-membered heterocyclo ring having 1 to 2 nitrogen atoms and 0-1 oxygen or sulfur atoms; and
n is zero, 1, or 2.

2 . The compound according to claim 1 having the structure of Formula (II):

or a salt thereof, wherein:
R 3 is:

X 1 is N and X 2 is S or O; or
X 1 is O and X 2 is CH; and
each R 3 is substituted with R 3a and zero to 3 R 3b .

3 . The compound according to claim 2 having the structure of Formula (IIa):

or a salt thereof, wherein:
R 1 is —CH 3 , —OCH 3 , —OCH 2 CH 3 , or —OCHF 2 ;
R 2 is F, Cl, —CN, —CH 3 , —CH 2 F, —CHF 2 , —CH 2 OH, —CH(CH 3 )OH, or —CH═CH 2 ;
R 3a is H, —CH 2 OH, —CH(CH 3 )OH, —CH 2 CH(CH 3 )OH, —CH(OH)C(CH 3 ) 3 , —CH(OH)(trifluoromethyl cyclopropyl), —CH(OH)(trifluoromethyl cyclobutyl), —CH(OH)(methyl cyclohexyl), —CH 2 NHC(O)CH 3 , —CH 2 NHC(O)CF 3 , —CH 2 NHC(O)CH 2 (phenyl), —CH 2 NHC(O)(morpholinyl), —CH 2 NHC(O)OCH 3 , —CH 2 NHC(O)NH(cyclopropyl), —CH 2 NHC(O)NH(phenyl), —CH 2 NHC(O)OCH 3 , —CH 2 NHC(O)OCH 2 CH 3 , —CH 2 NHC(O)OC(CH 3 ) 3 , —CH 2 NHC(O)OCH 2 CH(CH 3 ) 2 , —CH 2 NHC(O)OCH 2 C(CH 3 ) 3 , —CH 2 NHC(O)OCH 2 CH 2 F, —CH 2 NHC(O)OCH 2 CF 3 , —CH 2 NHC(O)OCH 2 CH 2 OCH 3 , —CH 2 NHS(O) 2 CH 3 , —CH 2 O(methyl pyrimidinyl), —CH 2 OC(O)(dimethylaminopyridinyl), —CH 2 OP(O)(OH) 2 , —C(O)OCH 3 , —CH 2 NHC(O)OR x , —CH 2 NHC(O)OCH 2 R x , or —CH 2 OC(O)NHR x ;
R x is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, benzo[d]oxazolyl, benzo[d]thiazolyl, pyrrolopyridinyl, tetrahydroisoquinolinyl, tetrahydrofuranyl, tetrahydropyranyl, imidazopyridinyl, or oxo-dihydrobenzo[d]oxazolyl, each substituted with zero to two substituents independently selected from F, Cl, Br, —CN, —OH, —CH 3 , —CF 3 , —CH 2 CH 2 OH, C 1-2 alkoxy, phenoxy, —NR a R a , —C(O)NR a R a , —C(O)OCH 3 , —C(O)OC(CH 3 ) 3 , —C(O)(morpholinyl), —CH(OH)CH 2 OH, —OCH 2 CH 2 OH, —OCH 2 CF 2 OH, —OCH 2 CH(CH 3 )OH, —CH═CH 2 , —NHC(O)CH 3 , —OCH 2 CH 2 N(CH 3 ) 2 , isoxazolyl, phenyl, pyrrolidinyl, thiophenyl, and methyl triazolyl; and
R 3b is H, F, Cl, —CH 3 , or —CHF 2 .

4 . The compound according to claim 1 or a salt thereof, wherein said compound is selected from:
(R)-(2-(6-chloro-3-methoxyquinolin-8-yl)-7,8-dihydro-[1,4]dioxino[2′,3′:3,4] benzo[1,2-d]thiazol-7-yl)methyl (2-methylpyrimidin-5-yl)carbamate (266);
(R)-(2-(6-chloro-3-methoxyquinolin-8-yl)-5-fluoro-7,8-dihydrobenzofuro[5,4-d]thiazol-7-yl) methyl (2-methylpyrimidin-5-yl)carbamate (267);
(R)-(2-(3-methoxy-6-methylquinolin-8-yl)-7,8-dihydro-[1,4]dioxino[2′,3′:3,4]benzo[1,2-d]thiazol-7-yl)methyl (2-methylpyrimidin-5-yl)carbamate (268);
(R)-(5-fluoro-2-(3-methoxy-6-methylquinolin-8-yl)-7,8-dihydrobenzofuro[5,4-d]thiazol-7-yl)methyl (2-methylpyrimidin-5-yl)carbamate (269);
(R)-(2-(6-chloro-3-ethoxyquinolin-8-yl)-5-fluoro-7,8-dihydrobenzofuro[5,4-d] thiazol-7-yl)methyl (2-methylpyrimidin-5-yl)carbamate (270);
(R)-(2-(6-chloro-3-ethoxyquinolin-8-yl)-7,

Assignees

• Bristol Myers Squibb Co

Inventors

• Zhang Xiaojun
• Priestley Eldon Scott
• Halpern Oz Scott
• Jiang Wen
• Reznik Samuel Kaye
• Richter Jeremy M

Classifications

• C07D515/14

  Ortho-condensed systems · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• C07D493/04

  Ortho-condensed systems · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/497

  containing further heterocyclic rings · CPC title